Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation

Violeta Serra¹, Ana Vivancos¹, Xose S. Puente¹, Enriqueta Felip¹, Daniel Silberschmidt¹, Ginevra Caratù¹, Josep-Lluís Parra¹, Leticia De Mattos-Arruda¹, Judit Grueso¹, Javier Hernández-Losa², Joaquín Arribas¹,³, Ludmila Prudkin¹, Paolo Nuciforo¹, Maurizio Scaltriti³, Joan Seoane¹,³, and José Baselga¹,⁵

INTRODUCTION

We describe the case of a 29-year-old nonsmoker female who, in 2003, underwent a bilateral mastectomy due to a malignant phyllodes tumor (MPT) and to a bilateral ductal carcinoma in situ (DCIS; Fig. 1A). The patient was treated with adjuvant tamoxifen from 2003 until 2008 (Fig. 1B). In November 2007, a nodule in the lower lobe of the left lung was detected in a control chest X-ray and was confirmed by computed tomography (CT) scan. A CT-guided needle aspiration of the lesion showed positivity for CK7 and TTF1, suggesting a primary lung adenocarcinoma. A left lower lobectomy and lymphadenectomy was subsequently performed and the pathology analysis showed a moderately differentiated invasive lung adenocarcinoma with a bronchioloalveolar pattern [non–small cell lung carcinoma (NSCLC)].

ABSTRACT

Genomic characterization of recurrent breast and lung tumors developed over the course of 10 years in a 29-year-old patient with a germline TP53 mutation (Li-Fraumeni Syndrome) identified oncogenic alterations in the HER2 and EGFR genes across all tumors, including HER2 amplifications, an EGFR-exon 20 insertion, and the first-in-humans HER2V659E mutation showing a phenotypic convergent evolution toward HER2 and EGFR alterations. Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, we treated the reminiscent metastatic lesions with a lapatinib-based therapy. A symptomatic and radiologic clinical response was achieved. HER2V659E sensitivity to lapatinib was confirmed in the laboratory.

SIGNIFICANCE: The precise knowledge of the genomic alterations present in tumors is critical to selecting the optimal treatment for each patient. Here, we report the molecular characterization and clinical response to a lapatinib-based therapy for the tumors of a Li-Fraumeni patient showing prevalence of HER2 and EGFR genomic alterations. Cancer Discov; 3(11):1238–44. © 2013 AACR.
Therapeutic Response to Novel HER2 Mutation

A Tumor sites

B Treatment timelines

Figure 1. Tumor sites and treatment timelines. A, the different tumor localization for the MPT of 2 cm, the right DCIS of 1 cm (pT1mic, grade 3) and the left DCISs of 0.8 and 1 cm (pTis, grade 3), the non–small cell lung carcinoma (NSCLC) of the left lung of 1.6 cm (pT2N1), and the NSCLC of the right lung of 1 cm (T1N2M1). The pulmonary lymphangitic carcinomatosis (PLC) and the pleural effusion (PE) were not measurable. The hilar lymph nodes N1(10) (n = 2, of 0.5 cm), peribronchial N1(12) (n = 1, of 1 cm), subcarinal N2(7) (n = 2, of 9 and 3 mm), and paratracheal N2(2R) (n = 2, of 1.6 and 1 cm), N2(4R) (n = 1, of 3 cm), and N1(10) (n = 1, of 2 cm by CT scan) are also shown. B, the treatment timelines received by the patient. From 2003 until 2008, the patient received adjuvant tamoxifen (TAM). In 2008, following the lobectomy she received six cycles of cisplatin/docetaxel (CDDP/DOC). After the segmentectomy in 2012, she received two cycles of cisplatin/pemetrexed (CDDP/PM). On the basis of the identification of HER2-V659E, she received Lap/P (oral daily lapatinib 1,000 mg/intravenous weekly paclitaxel 80 mg/m²).

(NSCLC) left] with visceral pleural invasion and involvement of three N1 lymph nodes without N2 involvement (pT2N1). The patient received four cycles of postoperative adjuvant cisplatin/docetaxel chemotherapy. In December 2011, a follow-up CT scan detected a 1-cm nodule in the right lower lobe of the lung. In parallel, the left lung images could not rule out the presence of pulmonary lymphangitic carcinomatosis (PLC). A segmentectomy of the right lower lung lobe and lymph node sampling was performed, showing a 1-cm TTF1⁺ invasive adenocarcinoma (suggesting lung carcinoma origin, NSCLC right) and extensive invasion of N2 lymph nodes in the 2R, 4R, and 7 regions [N2(2R), N2(4R), and N2(7)]. Given the pattern of tumors developed by the patient, genetic counseling was provided and revealed that the patient carried a TP53R248W germline mutation, leading to the diagnosis of Li-Fraumeni Syndrome (LFS). A postoperative CT scan confirmed the presence of PLC in the left lung, and the patient started cisplatin/pemetrexed chemotherapy. After two chemotherapy cycles, the patient reported the appearance of pain in the lower left thorax, and a CT scan showed the presence of a new pleural effusion in the left lung, a 2-cm nodule in the left hilus, and the previously detected PLC. As a result of whole-exome sequencing of her most recent tumor, the NSCLC right, an activating mutation HER2V659E was identified (Fig. 2). This result led us to consider that the tyrosine kinase inhibitor lapatinib could be a beneficial treatment option. Although this clinical decision was hypothesis-driven, we confirmed that HER2V659E-expressing cells were sensitive to lapatinib (Fig. 3). Lapatinib was given daily at a dose of 1,000 mg in combination with paclitaxel 80 mg/m². Shortly after starting therapy, the patient experienced pain relief at the lower left thorax and a pronounced improvement in breathing. Two months after the beginning of the treatment, a CT scan revealed a reduction in the pleural effusion in addition to shrinkage of the nodule in the left hilus (Fig. 4). Three months after the beginning of the lapatinib/paclitaxel treatment, the administration of paclitaxel was discontinued because of toxicity. Treatment with lapatinib continued, and trastuzumab, an anti-HER2 antibody, was added (initial dose of 8 mg/kg intravenously, followed by 6 mg/kg every 3 weeks). The observation that HER2 was amplified in circulating tumor cells (CTC) at this point in time, in addition to reports describing the clinical benefit of trastuzumab in the context of HER2-mutant NSCLC, supported this therapeutic approach (1, 2). The disease was further stabilized for an additional 6 months. In total, the clinical benefit lasted over 9 months.
RESERCH BRIEF

A Molecular alterations

<table>
<thead>
<tr>
<th>Year</th>
<th>Tumor sample</th>
<th>Tumor area (%)</th>
<th>ER (%)</th>
<th>PR (%)</th>
<th>HER2 IHC</th>
<th>HER2 FISH ratio</th>
<th>Chr 17 polysomy</th>
<th>EGFR (H score)</th>
<th>PTEN (H score)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>MPT</td>
<td>80</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>290</td>
<td>40 (60-40-0-0)</td>
</tr>
<tr>
<td></td>
<td>DCIS right</td>
<td>25</td>
<td>70</td>
<td>60</td>
<td>3+</td>
<td>3.58</td>
<td>No</td>
<td>ND</td>
<td>280 (0-10-0-90)</td>
</tr>
<tr>
<td></td>
<td>DCIS left</td>
<td>23</td>
<td>5</td>
<td>2</td>
<td>3+</td>
<td>4.15</td>
<td>No</td>
<td>ND</td>
<td>200 (0-0-100-0)</td>
</tr>
<tr>
<td>2008</td>
<td>NSCLC left</td>
<td>75</td>
<td>ND</td>
<td>ND</td>
<td>0</td>
<td>1.11</td>
<td>Yes</td>
<td>130</td>
<td>200 (0-30-40-30)</td>
</tr>
<tr>
<td>2012</td>
<td>NSCLC right</td>
<td>40</td>
<td>ND</td>
<td>ND</td>
<td>0</td>
<td>2.38</td>
<td>Yes</td>
<td>120</td>
<td>0 (100-0-0-0)</td>
</tr>
<tr>
<td></td>
<td>N2(4R)</td>
<td>35</td>
<td>ND</td>
<td>ND</td>
<td>0</td>
<td>1.71</td>
<td>Yes</td>
<td>280</td>
<td>50 (50-50-0-0)</td>
</tr>
</tbody>
</table>

B Exome sequencing

<table>
<thead>
<tr>
<th>Year</th>
<th>Tumor sample</th>
<th>HER2 EGFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>DCIS right</td>
<td>Amp</td>
</tr>
<tr>
<td></td>
<td>DCIS left</td>
<td>Amp</td>
</tr>
<tr>
<td>2008</td>
<td>NSCLC left</td>
<td>p.A767_S768insSVD</td>
</tr>
<tr>
<td>2012</td>
<td>NSCLC right</td>
<td>Amp, p.V659E</td>
</tr>
<tr>
<td></td>
<td>N2(4R)</td>
<td>20% cells Amp, p.A767_S768insSVD</td>
</tr>
</tbody>
</table>

C HER2 and EGFR alterations

<table>
<thead>
<tr>
<th>Year</th>
<th>Tumor sample</th>
<th>HER2</th>
<th>EGFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>DCIS right</td>
<td>Amp</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>DCIS left</td>
<td>Amp</td>
<td>—</td>
</tr>
<tr>
<td>2008</td>
<td>NSCLC left</td>
<td>—</td>
<td>p.A767_S768insSVD</td>
</tr>
<tr>
<td>2012</td>
<td>NSCLC right</td>
<td>Amp, p.V659E</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>N2(4R)</td>
<td>20% cells Amp</td>
<td>p.A767_S768insSVD</td>
</tr>
</tbody>
</table>

RESULTS

Molecular Characteristics of Tumors and CTCs

To identify potential actionable mutations, molecular pathologic analysis and exome sequencing of the MPT, DCISs, NSCLCs, and N2(4R) were performed (Fig. 1A and B).

Tumors were analyzed for the expression level of HER2, EGF receptor (EGFR), estrogen receptor (ER), progesterone receptor (PR), and PTEN by immunohistochemistry (IHC), and HER2 and EGFR gene amplification by FISH (Fig. 2A). High expression of EGFR was found in the MPT and in the N2(4R). HER2 overexpression was observed in both DCISs by IHC, and HER2 gene amplification was confirmed by FISH. All three lung lesions showed Chr17 polysomy (the chromosome that bears HER2). HER2 gene amplification was observed in NSCLC right in 65% of tumor cells, whereas no amplification was found in NSCLC left. Interestingly, 23% of tumor cells presented HER2 amplification in N2(4R) (Supplementary Fig. S1). Similarly, CTCs exhibited HER2 gene amplification. PTEN (and PIK3CA later on) were assessed because of their potential negative predictive value toward HER2/EGFR therapy (3–6). Although PIK3CA was wild-type in all samples, PTEN expression displayed intra- and intratumoral heterogeneity (Fig. 2A).

Whole-exome sequencing was performed on DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumor samples and from peripheral blood. We first identified the TP53-R248W mutation in the blood sample, confirming the diagnosis of LFS. However, the analysis of somatic variants presented two main difficulties. The percentage...
Therapeutic Response to Novel HER2 Mutation

A Biochemical activity of lapatinib

<table>
<thead>
<tr>
<th></th>
<th>Lapatinib</th>
<th>pHER2</th>
<th>HER2</th>
<th>pEGFR</th>
<th>EGFR</th>
<th>HER3</th>
<th>pAKT</th>
<th>AKT</th>
<th>pERK</th>
<th>ERK</th>
<th>p4EBP1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vector</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HER2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V659E</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B Antiproliferative activity of lapatinib

Figure 3. HER2V659E response to lapatinib in MCF10A cells. A, MCF10A cells overexpressing empty vector control, HER2 wild-type, or HER2V659E were treated with increasing doses of lapatinib (0, 0.125, 0.5, and 2 μmol/L). Immunoblotting of the total and phosphorylated proteins was conducted. pERK, pAKT, and p4EBP1 are downstream biomarkers of HER2 activation. B, MCF10A cells overexpressing empty vector control, HER2 wild-type, or HER2V659E treated with increasing doses of lapatinib. Cell proliferation was superior in HER2V659E-overexpressing cells. Error bars indicate SD of six independent experiments. Patient plasma concentration of 2.43 μg/mL based on a 1,250 mg/daily dose.

Figure 3 legend:

- **A** Biochemical activity of lapatinib
- **B** Antiproliferative activity of lapatinib

The following points are addressed in the text:

- **Novel HER2 Mutation**
  - The document describes a novel HER2 mutation, HER2V659E, which is identified in human tumors and is orthologous to the well-described HER2.
  - The mutation was identified in a transmembrane domain of HER2, HER2-p.V659E (69% mutation allele frequency, MAF), in the NSCLC right.
  - This mutation is a dinucleotide change [659 V(GTG)→E(GAA)] that has not been previously identified in human tumors and is orthogonal to the well-described oncogenic mutation found in rat Her2 [664 V(GTG)→E(GAG)] (7, 8).

- **HER2 Signaling**
  - The NSCLCs and the N2(4R) metastasis showed that these five tumors analyzed were in agreement with the HER2 amplification identified by FISH.
  - In addition, we identified an indel in exon 20 of EGFR [p.A766_A767insASV (9)], in the 2008 tumor, NSCLC left, accounting for up to 4% of all EGFR mutations (9), and although no functional studies of our patient-specific EGFR indel have been reported, neighboring insertions positioned at the loop following the C-helix of EGFR (for example, p.M766_A767insASV) have been shown to be activating mutations, indicating that the insertion harbored by our patient is likely to result in constitutive receptor activation.
  - HER2 and EGFR somatic mutations were confirmed by capillary sequencing (Supplementary Fig. S2B).

- **Phenotypic Convergent Evolution**
  - Interestingly, all tumors presented alterations in either HER2 or EGFR, both members of the HER family of tyrosine kinase receptors (Fig. 2C).
  - This indicates that HER-mediated signaling confers a selective advantage to the tumors and exemplifies a phenotypic convergent evolution toward a hyperactive HER pathway in all tumors of the LFS patient.

- **Comparison with Other Tumors**
  - A comparison of the somatic mutations and indels found in the five tumors analyzed showed that both DCISs were independent primary tumors, as they did not share any genomic alteration between them or with the rest of the tumors (Fig. 2B and Supplementary Table S1). However, the analysis of the NSCLCs and the N2(4R) metastasis showed that these three samples were related. In support of this assessment, the NSCLC left and the N2(4R) shared five indels (including EGFR p.A767_S768insSVD) and two nonsynonymous mutations, indicating that N2(4R) is a metastasis derived from the NSCLC left. On the other hand, N2(4R) and NSCLC right contained cells with HER2 amplification and, moreover, both NSCLCs shared one indel as well as polysomy of chromosomes 14, 16, and 17 (Supplementary Fig. S3A and S3B). These results suggested a phylogenetic relationship between them.
The identification of the HER2V659E in the most recent tumor prompted us to consider a therapeutic approach based on lapatinib. Studies using the MMTV-c-neu mouse model (a mouse model for breast cancer generated by the overexpression of the rat ortholog of HER2V659E) have shown evidence of the antitumor activity of lapatinib (10, 11).

We decided to functionally validate the sensitivity of HER2V659E to lapatinib in a preclinical in vitro model. HER2V659E was overexpressed in MCF10A cells and, as expected, high levels of HER2V659E led to hyperphosphorylation of the receptor and activation of the downstream signaling (Fig. 3A). Lapatinib inhibited HER2V659E and EGFR signaling in a dose-dependent manner. At low concentrations of lapatinib the HER2V659E-mutant cells were less sensitive to treatment than control cells, suggesting that the mutation could confer resistance to the treatment under these conditions, an observation that was extended to other EGFR/HER2–targeting agents (Supplementary Fig. S4). Importantly, when the inhibitor was used at a clinically achievable concentration of 2 μmol/L (12), MCF10A-expressing HER2V659E exhibited the same sensitivity to lapatinib as control cells (Fig. 3B). This reinforced our hypothesis that lapatinib at clinically achievable concentrations could be beneficial for the patient.

**DISCUSSION**

The identification of tumor driver genetic alterations, like the ones observed in the HER family of tyrosine kinase receptors, has led to novel therapeutic approaches that have dramatically improved patient outcomes. The paradigmatic example is the discovery of HER2 gene amplification in breast cancer and the clinical response of HER2-amplified tumors to the anti-HER2 monoclonal antibody trastuzumab (13, 14).

In addition to trastuzumab, the tyrosine kinase inhibitor lapatinib has also been approved as the therapy for HER2-amplified tumors, thanks to its ability to reversibly inhibit the intracellular tyrosine kinase activity of HER2 and downstream pathways, such as phosphoinositide 3-kinase (PI3K)/AKT and extracellular signal–regulated kinase (ERK; refs. 15, 16).

In addition to HER2 gene amplification, recent studies have shown that the HER2 gene can also be altered by somatic gene point mutations and insertions and deletions (indels;
Therapeutic Response to Novel HER2 Mutation

Functional analysis in preclinical models has shown that some of these HER2 gene mutations can induce oncogenesis and sensitize tumors to anti-HER2 treatments (23). However, little is known about the clinical response of HER2-mutant tumors to anti-HER2 therapies (1, 2), and novel irreversible EGFR/HER2 inhibitors are currently under clinical evaluation for the treatment of HER2-mutant metastatic breast cancer (NCT01111825) and NSCLC (NCT01827267). Here, we report the molecular characterization and clinical response to a lapatinib-based therapy for the tumors of a Li-Fraumeni patient showing prevalence of HER2 and EGFR oncogenic driver alterations.

In this study, we have performed whole-exome sequencing of the breast and lung tumors of a patient with LiF and identified driver genomic alterations that are actionable. The observation of a phenotypic convergent evolution of the tumors of the patient toward a hyperactive HER2 or EGFR pathways and the discovery of the HER2\(^{V659E}\) mutation (to our knowledge yet unreported in human samples) in her most recent tumors, as well as the identification of HER2 gene amplification in the patient CTCs, has allowed us to select a beneficial treatment for our patient. This work is an example of how personalized characterization of tumors can lead to therapeutic success. Despite the difficulty of using FFPE-archived material, we have observed that the patient generated different independent primary tumors and that the three most recent tumors were interrelated. Our data suggest that the two lung tumors and the lymph node metastasis located at N2(4R) have common origins and share tumor clones, most likely due to cross-seeding of metastasis. Despite the complexity and diversity of genomic alterations as well as the intricate relationship between the tumors, we observed alterations in HER2 and EGFR across all tumors. These results suggest a predisposition toward genomic alterations in HER family receptor tyrosine kinases in the context of the p53 germline mutation of the LiF. Whether this constitutes a general mechanism in patients with LiF and the exact mechanism involved in this phenomenon is something that needs to be evaluated.

Preclinical models that allowed the successful development of anti-HER2 therapies were based on this mutant form of HER2 (24, 25). Nevertheless, mutations affecting the V659 residue within the transmembrane domain of HER2 have not been identified in human tumors until now. Of note, the human HER2\(^{V659E}\) mutation necessarily implies a tandem dinucleotide change (T\(\rightarrow\)AA), a type of mutation that may arise from induced pyrimidine adducts in response to radiotherapy (26). The patient did not receive radiotherapy; however, the dinucleotide genomic alteration might have been caused by another type of irradiation, including the one from the frequent X-ray/CT scans conducted on the patient.

In summary, the thorough molecular characterization of tumors from a patient with LiF has led to the identification of alterations in HER2 and EGFR, among those the first-in-humans HER2\(^{V659E}\) mutation. The genomic characterization of the patient, together with the preclinical analysis showing that cells bearing the HER2\(^{V659E}\) mutation remain sensitive to clinically achievable doses of lapatinib, supported a lapatinib-based treatment for our patient. Notably, this therapeutic regimen led to clinical benefits with an objective decrease in tumor size and pleural effusion, relief of thoracic pain, and breathing improvement. The potential role of HER tyrosine kinase inhibitors in the therapy for HER2-mutant tumors deserves a systematic evaluation; therefore, a clinical trial with the irreversible HER2 inhibitor neratinib in metastatic breast cancer is currently under way (NCT01111825), and a “basket” clinical trial in patients with HER2 mutations from any other histologic origin is also in an advanced planning stage.

METHODS

Please see Supplementary Data for additional methods.

Exome Sequencing

The patient provided written informed consent for somatic and germline DNA analysis. FFPE tumor samples from six primary tumors, including a MPT, two DCISs (right and one left), two NSCLCs (left and right), and one metastatic lymph node N2(4R), along with a blood sample from the patient were subjected to whole-exome sequencing. Samples were initially assessed for tumor content based on a hematoxylin and eosin staining (Fig. 2A). Genomic DNA was extracted from FFPE tumor samples using the DNA RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Ambion) according to the manufacturer’s instructions. Germline DNA was extracted from whole blood using the QIAamp DNA Blood Midi Kit (Qiagen).

Exome libraries were constructed using a standard Illumina protocol (Genomic Sample Prep) with slight modifications for FFPE-derived DNA samples. One microgram of DNA was decross-linked by heat incubation, fragmented, ends repaired, and an adenine was ligated to each of the 3′ ends, where sample-specific adaptors were linked. Libraries were amplified using eight to 12 cycles of PCR, and exome enrichment was performed using specific biotinylated probes (SureSelect XT Human All Exon 50Mb; Agilent). After enrichment, the exome libraries were PCR-amplified, quantified, and loaded in a HiSeq2000 sequencer (Illumina). Paired-end 100 base sequences were obtained and aligned to the reference genome using Burrows-Wheeler Aligner. This yielded a median depth of coverage in targeted regions between 13× and 80×, and with more than 83% of the exome having at least 10 reads. Tumor samples were compared with normal DNA as previously described (27). To remove artifacts likely caused by cytosine deamination due to fixation/long-term storage of FFPE samples, and due to the presence of a low tumor cell content of some samples, the following filtering criteria were applied: somatic variants were called when supported by at least three reads, representing at least 10% of the total reads and with a minimum coverage of 35×. Putative somatic mutations were manually inspected to remove false positives in homopolymer stretches and close to indels.

Disclosure of Potential Conflicts of Interest

J. Baselga is employed as a consultant at Novartis and Genentech. No potential conflicts of interest were disclosed by the other authors.

The Editor-in-Chief of Cancer Discovery (J. Baselga) is an author of this article. In keeping with the AACR’s Editorial Policy, the paper was peer reviewed and a member of the AACR’s Publications Committee rendered the decision concerning acceptability.
Authors’ Contributions

Conception and design: V. Serra, J. Arribas, M. Scaltriti, J. Seoane, J. Baselga

Development of methodology: V. Serra, A. Vivanco, L. De Mattos-Arruda, J. Hernández-Losa, J. Baselga

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): V. Serra, A. Vivanco, E. Felip, G. Caratu, L. De Mattos-Arruda, J. Grueso, J. Hernández-Losa, J. Arribas, L. Prudkin, P. Nuciforo, J. Baselga

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): V. Serra, A. Vivanco, X.S. Puente, D. Silberschmidt, L. De Mattos-Arruda, J. Arribas, P. Nuciforo, J. Seoane, J. Baselga

Writing, review, and/or revision of the manuscript: V. Serra, A. Vivanco, E. Felip, L. De Mattos-Arruda, L. Prudkin, P. Nuciforo, M. Scaltriti, J. Seoane, J. Baselga

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): V. Serra, J.-L. Parra, L. De Mattos-Arruda

Study supervision: V. Serra, J. Seoane, J. Baselga

Acknowledgments

The authors thank the patient for her willingness to participate in this study and her family for always supporting her positive attitude. The authors also thank: Orland Díez and Judith Balmàquia (for genetic counseling), and Alicia Garcia and Cristina Saura (breast oncologists) for technical contribution and valuable discussions of the clinical case.

Grant Support

This work has been supported by the European Research Council grants (ERC AdG09 250244 to J. Baselga and ERC 205819 to J. Seoane), Instituto de Salud Carlos III (ISCIII) grants (P09/00623 to J. Baselga, PI070648 to J. Seoane, and PI1120536 to J. Arribas), and Redes Temáticas de Investigación Cooperativa en Salud (RETIC-ISCIII (RD06/06/0020/0075 to J. Baselga, RD12/0036/0043 to J. Seoane, and RD12/0048/0042 to J. Arribas), Asociación Española contra el Cancer AECC grants (to J. Seoane and J. Arribas), a Rafael del Pino Foundation grant (to J. Baselga), a private donation from the Orozco family through the Oncology Research Foundation, FERO (to J. Baselga), and the Banco Bilbao Vizcaya Argentaria (BBVA) Foundation (to J. Baselga).

Received March 26, 2013; revised July 11, 2013; accepted August 6, 2013; published OnlineFirst August 15, 2013.

REFERENCES

Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel \(HER_2^{V659E}\) Mutation

Violeta Serra, Ana Vivancos, Xose S. Puente, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2159-8290.CD-13-0132

Supplementary Material
Access the most recent supplemental material at:
http://cancerdiscovery.aacrjournals.org/content/suppl/2013/08/15/2159-8290.CD-13-0132.DC1

Cited articles
This article cites 27 articles, 9 of which you can access for free at:
http://cancerdiscovery.aacrjournals.org/content/3/11/1238.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://cancerdiscovery.aacrjournals.org/content/3/11/1238.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.